SCHEMBL25308018

SCHEMBL25308018

COC[C@@H]1C[C@@H](NC(=O)c2ncc(-c3cc(C(F)(F)F)ccc3OC3CC3)o2)CN1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.34
▸ CRHR1 P34998 3/20 0.34
▸ HDAC1 Q13547 3/20 0.33
▸ HDAC6 Q9UBN7 3/20 0.33
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ HTT P42858 2/20 0.33
▸ BTK Q06187 3/20 0.33
▸ TSHR P16473 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ SYK P43405 1/20 0.32
▸ JAK3 P52333 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ SSTR5 P35346 1/20 0.32
▸ TRPV1 Q8NER1 1/20 0.32
▸ FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24073210 0.92 PDE4B (0.34) RIPK1CRHR1HDAC1HDAC6MRGPRX4
SCHEMBL25838908 0.92 PDE4B (0.34) RIPK1CRHR1HDAC1HDAC6MRGPRX4
SCHEMBL24073211 0.88 CETP (0.35) CRHR1HDAC1HDAC6BTKSSTR5
SCHEMBL27418557 0.88 CETP (0.35) CRHR1HDAC1HDAC6BTKSSTR5
SCHEMBL24073560 0.88 CETP (0.35) CRHR1HDAC1HDAC6BTKSSTR5
SCHEMBL24073558 0.88 CETP (0.35) CRHR1HDAC1HDAC6BTKSSTR5
SCHEMBL25260209 0.88 ACKR3 (0.34) MRGPRX4TRPV1FAAH
SCHEMBL25305510 0.83 HDAC1 (0.50) RIPK1HDAC1HDAC6FAAH
SCHEMBL25258088 0.83 HDAC1 (0.50) RIPK1HDAC1HDAC6FAAH
SCHEMBL28971352 0.83 HDAC1 (0.50) RIPK1HDAC1HDAC6FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157834-B1 N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION MISSION THERAPEUTICS LTD (GB) 2024-07-03 — — EP disclosed
US-20230219939-A1 N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION MISSION THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219939-A1 N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION USP30, UQCRC1, NDUFAF1 RIPK1 2377/4885CRHR1 3882/4885HDAC1 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback